mainPic
about PharmaEngine

LATEST NEWS

2014/10/17 - Event

PEP503 (NBTXR3) phase II/III registration trial (pivotal study) in soft tissue sarcoma has approved to start in France by ANSM

Vision

To be one of the most innovative and successful biopharmaceutical companies specializing for the treatment of cancer and Asian prevalent diseases.

Objectives

PharmaEngine, Inc. is a specialty pharma company which adopts the "no research, development only model" and the "networked pharma model" for new drug development. We license in drug candidates ranging from preclinical to clinical stages and further develop the projects in niche markets.